Every 8-K that Whitehawk Therapeutics, Inc. (WHWK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WHWK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WHWK filings page.
Whitehawk Therapeutics, Inc. (WHWK) expanded its board of directors from nine to ten members and appointed Vijay Iyengar, M.D. as a Class III director, effective September 9, 2026, with a term expiring at the 2029 annual meeting of stockholders. Dr. Iyengar is a seasoned oncology executive, having held senior global medical affairs, strategy, corporate development and commercial roles at Incyte and Novartis, and earlier experience at McKinsey. As a non-employee director, he will receive the standard outside director cash retainer and an initial stock option grant that vests monthly over three years. Whitehawk highlights that his background supports its focus on developing antibody-drug conjugate cancer treatments and advancing its clinical-stage ADC portfolio.
Whitehawk Therapeutics, a clinical-stage oncology company focused on antibody drug conjugates, reported second quarter 2026 results. Cash, cash equivalents and short-term investments were $190.0 million as of June 30, 2026, up from $145.7 million at December 31, 2025, and are expected to fund operations into 2H 2028.
The company continued enrolling patients in Phase 1 trials of HWK-007 and HWK-016 and plans to initiate a Phase 1 study of HWK-206 in small-cell lung cancer and neuroendocrine tumors in Q3 2026, with initial Phase 1 data for HWK-007 and HWK-016 anticipated in 1H 2027. Whitehawk expanded its platform through an option agreement with Hangzhou DAC for CPT113-based ADCs and a global collaboration with Biocytogen to access up to five bispecific antibodies using the RenLite platform.
Research and development expenses were $12.9 million for the quarter, compared with $48.8 million a year earlier, when results included a $38.0 million up-front license fee to WuXi Biologics. Net loss was $16.6 million, or $0.20 per share, versus a net loss of $52.6 million, or $0.76 per share, in the prior-year quarter.
Whitehawk Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where investors voted on director elections, executive pay and the company’s auditor. A total of 40,375,023 common shares, representing approximately 82% of voting power as of April 17, 2026, were present, establishing a quorum.
Stockholders elected three Class III directors – Behzad Aghazadeh, Ph.D., Richard Maroun and Emma Reeve – to terms ending at the 2029 annual meeting. On an advisory basis, stockholders approved the compensation of named executive officers. They also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Whitehawk Therapeutics, Inc. disclosed an option agreement with Hangzhou DAC that expands its antibody-drug conjugate (ADC) pipeline by providing access to the CPT113 linker-payload for use in up to five additional, internally developed ADC programs. Whitehawk will select targets, source antibodies, and retain global rights and full control of these programs, and expects to submit multiple Investigational New Drug applications over the next 12–24 months.
External programs using CPT113, including Hangzhou DAC’s DXC006 and Johnson & Johnson’s JNJ-95437446, have shown early clinical and preclinical data that support continued development of this technology. Whitehawk’s own Phase 1 dose-escalation trials for HWK-007 and HWK-016 are enrolling, with initial data expected in the first half of 2027, while an IND for HWK-206 is anticipated mid-year. The company also highlights typical development, safety, and financing risks that could cause actual outcomes to differ from current expectations.
Whitehawk Therapeutics entered into a private investment in public equity financing expected to raise gross proceeds of approximately $87.5 million. The company is selling 4,330,866 shares of common stock at $3.92 per share and 17,991,021 pre-funded warrants at $3.9199 each, with an exercise price of $0.0001 per share. Closing is expected on May 14, 2026, subject to customary conditions, and certain executives, directors and affiliated funds committed $39.75 million. Net proceeds, together with existing cash, are intended for working capital and advancing Whitehawk’s antibody drug conjugate pipeline, and are expected to extend the company’s cash runway into the second half of 2028. Executives and directors agreed to 60‑day lock-ups, and the company plans to file a resale registration statement for the new securities.
Whitehawk Therapeutics reported first quarter 2026 results, highlighting its transition to a pure R&D oncology company. Cash, cash equivalents and short-term investments were $123.0 million as of March 31, 2026, which the company anticipates will fund operations into 2028.
Whitehawk posted a net loss of $22.2 million for the quarter, compared with net income of $73.0 million a year earlier, when results included an $87.4 million gain on the sale of Aadi Subsidiary and $7.1 million of product sales. Research and development expenses rose to $17.2 million, driven in part by $5.3 million of development milestones under a WuXi Biologics license agreement.
Operationally, the company is enrolling Phase 1 trials for HWK‑007 and HWK‑016, plans to submit an IND for HWK‑206 in mid‑2026 with Phase 1 recruitment targeted for Q3 2026, and expects initial Phase 1 data for HWK‑007 and HWK‑016 in the first half of 2027.
Whitehawk Therapeutics reported full-year 2025 results, highlighting a transition to a pure-play oncology ADC company with three clinical and near-clinical assets. Cash, cash equivalents and short-term investments were $145.7 million as of December 31, 2025, up from $47.2 million a year earlier, and are expected to fund operations into 2028.
Product revenue fell to zero in 2025 from $25.98 million in 2024 following the divestiture of the AADI subsidiary, while net loss narrowed to $20.6 million from $63.7 million, aided by an $87.3 million gain on that sale. The company is actively recruiting Phase 1 trials for PTK7-targeted ADC HWK-007 and MUC16-targeted ADC HWK-016, plans an IND for HWK-206 in mid-2026, and expects initial Phase 1 data for HWK-007 and HWK-016 in the first half of 2027.
Whitehawk Therapeutics reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, and therefore is not subject to the liabilities of Section 18 of the Exchange Act, unless specifically incorporated by reference elsewhere.